Nelmastobart plus docetaxel for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug, nelmastobart, combined with the chemotherapy docetaxel, for people with advanced non-small cell lung cancer that has a high level of a protein called BTN1A1. It is for patients who have already tried other treatments and are looking for a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (stage IIIb, IIIc, or IV) non-small cell lung cancer that has come back or spread.
- Your tumor has a high level of a protein called BTN1A1 (a score of 50% or higher).
- You have already had at least one type of chemotherapy or immunotherapy, and if you have a specific gene mutation, also a targeted therapy.
- You are able to take care of yourself and are up and about more than half of the day (ECOG 0-1).
- Your major organs (liver, kidneys, heart, bone marrow) are working well enough.
- You are willing to provide a sample of your stored tumor tissue for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new drug combination (SYS6010 plus enlonstobart) works better than standard immunotherapy with chemotherapy for patients with advanced non-small cell lung cancer. You may qualify if you have not received prior cancer treatment and have a specific marker (PD-L1) on your tumor.
This trial tests whether giving the immunotherapy drug Benmelstobart after surgery can help prevent return of a specific type of lung cancer. It is for people with stage IB, grade 3 (poorly differentiated) lung adenocarcinoma that has been completely removed.
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
This trial tests a new investigational drug combined with chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if it is safe and works better than current treatments.
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
This Phase 3 trial compares AL2846 pills plus TQB2450 injections against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer. You may qualify if your cancer has progressed after platinum chemotherapy and immunotherapy, and if certain tumor genetic tests are negative.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.